Le Lézard
Classified in: Business
Subjects: ERN, ERP

Braskem's Recurring EBITDA in the quarter was US$187 million, 34% higher than 2Q23


Green PE's operational performance was above nominal capacity of 260,000 tons/year with utilization rate of 108% in the quarter

SÃO PAULO, Nov. 9, 2023 /PRNewswire/ -- BRASKEM S.A. (B3: BRKM3, BRKM5 and BRKM6; NYSE: BAK; LATIBEX: XBRK) the largest resin producer in the Americas and the world's leading biopolymers producer, presents its 3Q23 Earnings Release.

3Q23 HIGHLIGHTS 

CONSOLIDATED

The full earnings release is available on the Company's IR website: www.braskem-ri.com.br/home-en

Braskem will host conference calls to discuss its Results Thursday, November 09 at 10:00 a.m. US ET.

Additional information may be obtained from the Investor Relations Department at +55 11 3576-9531 or [email protected].

 

SOURCE Braskem


These press releases may also interest you

at 07:16
OneConnect Financial Technology Co., Ltd. ("OneConnect" or the "Company") , a leading technology-as-a-service provider for the financial services industry in China, today announced its unaudited financial results for the fourth quarter and full year...

at 07:15
CodeSignal, the leading skills platform, has been named #2 in Education on Fast Company's prestigious World's Most Innovative Companies of 2025 list. This annual ranking honors organizations that are transforming industries and shaping the future...

at 07:15
Artisight, Inc., provider of a Smart Hospital Platform powered by artificial intelligence (AI), is deepening its collaboration with KARL STORZ, a worldwide leader in Operating Room (OR) integration, and NVIDIA, to bring the next generation of...

at 07:07
Hamilton Zanze, a leading San Francisco-based multifamily real estate investment firm, today announced it has sponsored the purchase of 1400 Chestnut Apartments, a 200-home midrise apartment community in Chattanooga, Tenn. The acquisition closed on...

at 07:07
Since Mitsubishi Motors North America, Inc. (MMNA) unveiled its Momentum 2030 long-range U.S. business plan, the company has seen a spike in interest from prospective business partners looking to join the company's dealer ranks.  The Momentum 2030...

at 07:05
Stoke Therapeutics, Inc. is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential...



News published on and distributed by: